Karyopharm Therapeutics | KPTI - Current Liabilities


Karyopharm Therapeutics reported $92.06M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Abbott USD 18.38B 1.88B Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Takeda JPY 2.61T 470.53B Dec/2025
Tectonic Therapeutic USD 9.67M 293K Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Ultragenyx Pharmaceutical USD 384M 43.98M Dec/2025
Xencor USD 95.91M 9.42M Dec/2025